Takeda Pharmaceutical shares fall 2.69% intraday due to a 3.7% revenue decline at constant exchange rates.

Takeda Pharmaceutical Company Limited fell 2.69% intraday, with the company reporting a 3.7% decline in revenue at constant exchange rates and an 8.4% decline at actual exchange rates due to generic erosion of VYVANSE. Despite this, the company's net profit rose 30% due to lower impairment and restructuring expenses, and it reaffirmed its full-year outlook. Additionally, Takeda achieved important milestones in its R&D pipeline, including positive results from two pivotal Phase 3 studies of Oveporexton in Narcolepsy Type 1.